CytomX Cost Of Revenue vs Income Before Tax Analysis

CTMX Stock

USD 1.59 0.01 0.63%

CytomX Therapeutics financial indicator trend analysis is way more than just evaluating CytomX Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytomX Therapeutics is a good investment. Please check the relationship between CytomX Therapeutics Cost Of Revenue and its Income Before Tax accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytomX Therapeutics Cost Of Revenue account and Income Before Tax. At this time, the significance of the direction appears to have no relationship.

The correlation between CytomX Therapeutics' Cost Of Revenue and Income Before Tax is 0.0. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of CytomX Therapeutics, assuming nothing else is changed. The correlation between historical values of CytomX Therapeutics' Cost Of Revenue and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of CytomX Therapeutics are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Cost Of Revenue i.e., CytomX Therapeutics' Cost Of Revenue and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on CytomX Therapeutics income statement and represents the costs associated with goods and services CytomX Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on CytomX Therapeutics income statement and is an important metric when analyzing CytomX Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from CytomX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.Tax Provision is likely to rise to about 3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.8 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	69.6M	53.2M	99.0M	53.9M
Total Revenue	69.6M	53.2M	101.2M	54.2M

Gross Profit Total Revenue

CytomX Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.88	0.89	0.7	0.65	0.9	0.6	0.56	-0.84	-0.6	0.67	0.85	0.63	-0.01	0.38	1.0	0.19	-0.12	-0.12	0.33	0.9	0.86	-0.88	0.9	0.4	0.89
Short Long Term Debt Total	0.88		0.69	0.52	0.78	0.73	0.49	0.38	-0.73	-0.44	0.87	0.73	0.55	0.18	0.41	0.87	0.15	-0.01	-0.01	0.07	0.85	0.63	-0.93	0.79	0.28	0.65
Other Current Liab	0.89	0.69		0.86	0.41	0.82	0.8	0.71	-0.77	-0.79	0.43	0.81	0.81	-0.25	0.26	0.85	0.31	-0.15	-0.15	0.65	0.73	0.75	-0.8	0.9	0.67	0.89
Total Current Liabilities	0.7	0.52	0.86		0.09	0.81	0.74	0.9	-0.52	-0.94	0.21	0.57	0.75	-0.39	0.25	0.64	0.5	-0.32	-0.32	0.84	0.69	0.6	-0.75	0.83	0.8	0.86
Total Stockholder Equity	0.65	0.78	0.41	0.09		0.36	0.15	-0.12	-0.63	0.05	0.78	0.59	0.19	0.32	0.26	0.7	-0.33	0.28	0.28	-0.29	0.61	0.31	-0.6	0.43	-0.15	0.24
Other Liab	0.9	0.73	0.82	0.81	0.36		0.55	0.69	-0.7	-0.69	0.49	0.71	0.59	0.0	0.31	0.89	0.35	-0.22	-0.22	0.51	0.91	0.88	-0.81	0.87	0.44	0.95
Property Plant And Equipment Net	0.6	0.49	0.8	0.74	0.15	0.55		0.64	-0.49	-0.74	0.15	0.57	0.99	-0.44	0.51	0.53	0.21	-0.14	-0.14	0.62	0.4	0.52	-0.6	0.69	0.82	0.68
Current Deferred Revenue	0.56	0.38	0.71	0.9	-0.12	0.69	0.64		-0.22	-0.98	0.08	0.28	0.66	-0.39	0.18	0.5	0.49	-0.68	-0.68	0.79	0.59	0.49	-0.67	0.69	0.88	0.74
Net Debt	-0.84	-0.73	-0.77	-0.52	-0.63	-0.7	-0.49	-0.22		0.32	-0.64	-1.0	-0.5	0.08	-0.35	-0.83	-0.28	-0.38	-0.38	-0.23	-0.63	-0.8	0.63	-0.77	-0.13	-0.76
Retained Earnings	-0.6	-0.44	-0.79	-0.94	0.05	-0.69	-0.74	-0.98	0.32		-0.13	-0.38	-0.76	0.43	-0.19	-0.54	-0.5	0.57	0.57	-0.82	-0.59	-0.5	0.72	-0.73	-0.93	-0.76
Accounts Payable	0.67	0.87	0.43	0.21	0.78	0.49	0.15	0.08	-0.64	-0.13		0.61	0.22	0.48	0.18	0.69	0.05	0.12	0.12	-0.18	0.63	0.45	-0.73	0.58	-0.05	0.39
Cash	0.85	0.73	0.81	0.57	0.59	0.71	0.57	0.28	-1.0	-0.38	0.61		0.58	-0.13	0.39	0.83	0.29	0.35	0.35	0.29	0.63	0.81	-0.65	0.8	0.22	0.79
Non Current Assets Total	0.63	0.55	0.81	0.75	0.19	0.59	0.99	0.66	-0.5	-0.76	0.22	0.58		-0.38	0.52	0.58	0.18	-0.17	-0.17	0.62	0.45	0.54	-0.65	0.72	0.82	0.7
Non Currrent Assets Other	-0.01	0.18	-0.25	-0.39	0.32	0.0	-0.44	-0.39	0.08	0.43	0.48	-0.13	-0.38		-0.34	0.05	-0.38	0.02	0.02	-0.5	0.11	-0.05	0.0	-0.08	-0.55	-0.21
Other Assets	0.38	0.41	0.26	0.25	0.26	0.31	0.51	0.18	-0.35	-0.19	0.18	0.39	0.52	-0.34		0.37	-0.1	0.11	0.11	0.07	0.25	0.36	-0.31	0.39	0.24	0.35
Cash And Short Term Investments	1.0	0.87	0.85	0.64	0.7	0.89	0.53	0.5	-0.83	-0.54	0.69	0.83	0.58	0.05	0.37		0.12	-0.11	-0.11	0.27	0.91	0.85	-0.86	0.87	0.33	0.85
Net Receivables	0.19	0.15	0.31	0.5	-0.33	0.35	0.21	0.49	-0.28	-0.5	0.05	0.29	0.18	-0.38	-0.1	0.12		-0.03	-0.03	0.42	0.2	0.36	-0.29	0.35	0.35	0.47
Good Will	-0.12	-0.01	-0.15	-0.32	0.28	-0.22	-0.14	-0.68	-0.38	0.57	0.12	0.35	-0.17	0.02	0.11	-0.11	-0.03		1.0	-0.34	-0.24	-0.05	0.26	-0.16	-0.56	-0.18
Common Stock Total Equity	-0.12	-0.01	-0.15	-0.32	0.28	-0.22	-0.14	-0.68	-0.38	0.57	0.12	0.35	-0.17	0.02	0.11	-0.11	-0.03	1.0		-0.34	-0.24	-0.05	0.26	-0.16	-0.56	-0.18
Common Stock Shares Outstanding	0.33	0.07	0.65	0.84	-0.29	0.51	0.62	0.79	-0.23	-0.82	-0.18	0.29	0.62	-0.5	0.07	0.27	0.42	-0.34	-0.34		0.29	0.34	-0.36	0.49	0.78	0.62
Short Term Investments	0.9	0.85	0.73	0.69	0.61	0.91	0.4	0.59	-0.63	-0.59	0.63	0.63	0.45	0.11	0.25	0.91	0.2	-0.24	-0.24	0.29		0.71	-0.89	0.8	0.34	0.78
Non Current Liabilities Total	0.86	0.63	0.75	0.6	0.31	0.88	0.52	0.49	-0.8	-0.5	0.45	0.81	0.54	-0.05	0.36	0.85	0.36	-0.05	-0.05	0.34	0.71		-0.61	0.79	0.28	0.93
Inventory	-0.88	-0.93	-0.8	-0.75	-0.6	-0.81	-0.6	-0.67	0.63	0.72	-0.73	-0.65	-0.65	0.0	-0.31	-0.86	-0.29	0.26	0.26	-0.36	-0.89	-0.61		-0.84	-0.56	-0.75
Other Current Assets	0.9	0.79	0.9	0.83	0.43	0.87	0.69	0.69	-0.77	-0.73	0.58	0.8	0.72	-0.08	0.39	0.87	0.35	-0.16	-0.16	0.49	0.8	0.79	-0.84		0.54	0.9
Other Stockholder Equity	0.4	0.28	0.67	0.8	-0.15	0.44	0.82	0.88	-0.13	-0.93	-0.05	0.22	0.82	-0.55	0.24	0.33	0.35	-0.56	-0.56	0.78	0.34	0.28	-0.56	0.54		0.56
Total Liab	0.89	0.65	0.89	0.86	0.24	0.95	0.68	0.74	-0.76	-0.76	0.39	0.79	0.7	-0.21	0.35	0.85	0.47	-0.18	-0.18	0.62	0.78	0.93	-0.75	0.9	0.56

Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	341.3M	358.7M	339.4M	260.9M	205.2M	284.4M
Other Current Liab	27.2M	19.9M	30.6M	24.5M	17.6M	17.9M
Total Current Liabilities	85.6M	100.9M	106.3M	152.6M	155.9M	82.7M
Total Stockholder Equity	51.1M	49.8M	89.4M	(85.8M)	(47.4M)	(45.1M)
Other Liab	179.7M	186.3M	125.7M	180.1M	207.1M	151.2M
Property Plant And Equipment Net	32.8M	29.4M	25.3M	21.0M	16.2M	14.9M
Current Deferred Revenue	51.4M	74.9M	69.3M	121.3M	132.3M	138.9M
Net Debt	(163.6M)	(167.0M)	(187.5M)	(175.6M)	(3.2M)	(3.4M)
Retained Earnings	(417.2M)	(450.1M)	(533.7M)	(722.9M)	(723.4M)	(687.3M)
Accounts Payable	4.2M	3.0M	2.8M	2.8M	1.5M	2.7M
Cash	188.4M	191.9M	205.5M	193.7M	17.2M	16.3M
Non Current Assets Total	37.9M	34.7M	29.1M	23.8M	22.2M	19.8M
Non Currrent Assets Other	2.9M	(3.4M)	(3.7M)	(3.6M)	83K	78.9K
Other Assets	2.9M	25.6M	1.8M	944K	1.1M	1.0M
Cash And Short Term Investments	296.1M	316.1M	305.2M	193.7M	174.5M	253.8M
Net Receivables	13K	798K	790K	36.0M	3.4M	5.6M
Common Stock Shares Outstanding	45.3M	46.1M	64.1M	65.7M	73.8M	48.9M
Short Term Investments	188.6M	107.7M	124.3M	99.7M	157.3M	117.8M
Liabilities And Stockholders Equity	341.3M	358.7M	339.4M	260.9M	205.2M	284.4M
Non Current Liabilities Total	204.6M	207.9M	143.7M	194.0M	96.7M	167.7M
Other Current Assets	7.2M	7.1M	4.3M	7.5M	5.0M	5.2M
Other Stockholder Equity	468.3M	500.0M	623.3M	637.1M	675.9M	709.7M
Total Liab	290.2M	308.9M	250.0M	346.6M	252.6M	250.4M
Property Plant And Equipment Gross	32.8M	29.4M	25.3M	21.0M	30.9M	16.4M
Total Current Assets	303.3M	324.0M	310.3M	237.1M	182.9M	264.6M
Accumulated Other Comprehensive Income	57K	(47K)	(242K)	10K	95K	99.8K
Short Term Debt	2.8M	3.2M	3.6M	4.1M	4.6M	4.7M
Intangible Assets	1.3M	1.2M	1.0M	875K	729K	1.1M
Property Plant Equipment	6.9M	32.8M	7.0M	6.0M	6.9M	8.3M
Net Tangible Assets	48.9M	47.7M	87.4M	(2.4M)	(2.8M)	(2.7M)
Retained Earnings Total Equity	(417.2M)	(450.1M)	(533.7M)	(623.6M)	(561.2M)	(533.1M)
Capital Surpluse	446.0M	468.3M	500.0M	623.3M	716.8M	474.2M
Non Current Liabilities Other	850K	207.9M	143.7M	262M	3.9M	3.7M
Net Invested Capital	51.1M	49.8M	89.4M	(85.8M)	(47.4M)	(45.1M)
Net Working Capital	217.7M	223.1M	204.0M	84.5M	27.0M	25.7M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CytomX Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CytomX Therapeutics' short interest history, or implied volatility extrapolated from CytomX Therapeutics options trading.

Pair Trading with CytomX Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CytomX Stock

0.69	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr
0.76	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.79	ENVB	Enveric Biosciences Financial Report 20th of May 2024	Pair Corr

The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.

The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether CytomX Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytomX Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomx Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomx Therapeutics Stock:

How To Invest In CytomX

Details

Is CytomX Stock a good investment?

Details

What is CytomX Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for CytomX Stock analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets

Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.01)

Revenue Per Share

1.371

Quarterly Revenue Growth

0.322

Return On Assets

(0.02)

Return On Equity

(54.75)

The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytomX Cost Of Revenue vs Income Before Tax Analysis

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Income Before Tax

CytomX Therapeutics fundamental ratios Correlations

CytomX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytomX Therapeutics fundamental ratios Accounts

Pair Trading with CytomX Therapeutics

Moving together with CytomX Stock

Complementary Tools for CytomX Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Common Stock Total Equity	+ 1.0	Good Will
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.95	Other Liab
Total Liab	+ 0.93	Non Current Liabilities Total
Short Term Investments	+ 0.91	Other Liab

Cash	- 1.0	Net Debt
Retained Earnings	- 0.98	Current Deferred Revenue
Retained Earnings	- 0.94	Total Current Liabilities
Other Stockholder Equity	- 0.93	Retained Earnings
Inventory	- 0.93	Short Long Term Debt Total
Inventory	- 0.89	Short Term Investments